{"transactions":[{"id":4638456,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":31042,"kind":"organization","name":"GordonMD Global Investments LP","position":1,"cik":"0002039349","reported_name":"GordonMD Global Investments LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":31043,"kind":"organization","name":"GordonMD Long Biased Master Fund LP","position":2,"cik":"0002103789","reported_name":"GordonMD Long Biased Master Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":31044,"kind":"organization","name":"GordonMD Long Biased GP LLC","position":3,"cik":"0002103778","reported_name":"GordonMD Long Biased GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":31045,"kind":"person","name":"Gordon Craig D","position":4,"cik":"0002103811","reported_name":"Gordon Craig D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrant","published_at":"2026-10-09T18:39:47.000Z","date":"2026-10-01","kind":"purchase","planned":false,"acquired":true,"shares":7172000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Exercise price of $3.5, subject to adjustments as set forth in the Common Stock Purchase Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The combined public offering price for each share of common stock and accompanying Common Stock Purchase Warrant is $2.90."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Common Stock Purchase Warrant will not be exercisable unless and until (i) the issuer's stockholders approve an amendment to the issuer's amended and restated certificate of incorporation to increase the number of authorized shares of Common Stock (the \"Charter Amendment\") and (ii) the Charter Amendment is filed with, and becomes effective under the laws of, the State of Delaware (the date on which the Charter Amendment becomes effective, the \"Charter Amendment Effective Date\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Common Stock Purchase Warrant will expire on the earlier of (i) the fifth anniversary of the Charter Amendment Effective Date and (ii) the 30th calendar day following the later of the Charter Amendment Effective Date and the date on which the issuer publicly discloses the results of the overall survival analysis for its Phase 1 monotherapy study of MICVO in second-line and later recurrent or metastatic head and neck squamous cell carcinoma."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities to which this filing relates are held directly by GordonMD Long Biased Master Fund LP (the \"Master Fund\") to which GordonMD Global Investments LP (the \"Investment Manager\") serves as investment manager. Craig D. Gordon (\"Mr. Gordon\") is the managing member of GordonMD Long Biased GP LLC (the \"GP\"), the general partner of the Master Fund. Each of the Master Fund, the GP and Mr. Gordon disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":7172000,"derivative":{"exercise_price":3.5,"underlying":"Common Stock","underlying_shares":7172000},"source":{"system":"sec-edgar","filing":"0000919574-26-006815","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2103811/000091957426006815/ownership.xml","form_type":"4/A","original_submission_date":"2026-10-02"}},{"id":4634066,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":31042,"kind":"organization","name":"GordonMD Global Investments LP","position":1,"cik":"0002039349","reported_name":"GordonMD Global Investments LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":31043,"kind":"organization","name":"GordonMD Long Biased Master Fund LP","position":2,"cik":"0002103789","reported_name":"GordonMD Long Biased Master Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":31044,"kind":"organization","name":"GordonMD Long Biased GP LLC","position":3,"cik":"0002103778","reported_name":"GordonMD Long Biased GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":31045,"kind":"person","name":"Gordon Craig D","position":4,"cik":"0002103811","reported_name":"Gordon Craig D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrant","published_at":"2026-10-02T16:35:26.000Z","date":"2026-10-01","kind":"purchase","planned":false,"acquired":true,"shares":7546766,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Exercise price of $3.5, subject to adjustments as set forth in the Common Stock Purchase Warrant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The combined public offering price for each share of common stock and accompanying Common Stock Purchase Warrant is $2.90."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Common Stock Purchase Warrant will not be exercisable unless and until (i) the issuer's stockholders approve an amendment to the issuer's amended and restated certificate of incorporation to increase the number of authorized shares of Common Stock (the \"Charter Amendment\") and (ii) the Charter Amendment is filed with, and becomes effective under the laws of, the State of Delaware (the date on which the Charter Amendment becomes effective, the \"Charter Amendment Effective Date\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Common Stock Purchase Warrant will expire on the earlier of (i) the fifth anniversary of the Charter Amendment Effective Date and (ii) the 30th calendar day following the later of the Charter Amendment Effective Date and the date on which the issuer publicly discloses the results of the overall survival analysis for its Phase 1 monotherapy study of MICVO in second-line and later recurrent or metastatic head and neck squamous cell carcinoma."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities to which this filing relates are held directly by GordonMD Long Biased Master Fund LP (the \"Master Fund\") to which GordonMD Global Investments LP (the \"Investment Manager\") serves as investment manager. Craig D. Gordon (\"Mr. Gordon\") is the managing member of GordonMD Long Biased GP LLC (the \"GP\"), the general partner of the Master Fund. Each of the Master Fund, the GP and Mr. Gordon disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":7546766,"derivative":{"exercise_price":3.5,"underlying":"Common Stock","underlying_shares":7546766},"source":{"system":"sec-edgar","filing":"0000919574-26-006609","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2039349/000091957426006609/ownership.xml","form_type":"4"}},{"id":4634065,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":31042,"kind":"organization","name":"GordonMD Global Investments LP","position":1,"cik":"0002039349","reported_name":"GordonMD Global Investments LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":31043,"kind":"organization","name":"GordonMD Long Biased Master Fund LP","position":2,"cik":"0002103789","reported_name":"GordonMD Long Biased Master Fund LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":31044,"kind":"organization","name":"GordonMD Long Biased GP LLC","position":3,"cik":"0002103778","reported_name":"GordonMD Long Biased GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":31045,"kind":"person","name":"Gordon Craig D","position":4,"cik":"0002103811","reported_name":"Gordon Craig D","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.001 per share (\"Common Stock\")","published_at":"2026-10-02T16:35:26.000Z","date":"2026-10-01","kind":"purchase","planned":false,"acquired":true,"shares":5517000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The combined public offering price for each share of common stock and accompanying Common Stock Purchase Warrant is $2.90."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities to which this filing relates are held directly by GordonMD Long Biased Master Fund LP (the \"Master Fund\") to which GordonMD Global Investments LP (the \"Investment Manager\") serves as investment manager. Craig D. Gordon (\"Mr. Gordon\") is the managing member of GordonMD Long Biased GP LLC (the \"GP\"), the general partner of the Master Fund. Each of the Master Fund, the GP and Mr. Gordon disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any."}],"balance_after":15541909,"source":{"system":"sec-edgar","filing":"0000919574-26-006609","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2039349/000091957426006609/ownership.xml","form_type":"4"}},{"id":3241134,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-08T11:41:12.000Z","date":"2026-09-04","kind":"grant","planned":false,"acquired":true,"shares":2503050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of September 4, 2026 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":2503050,"derivative":{"exercise_price":3.89,"expiration_date":"2036-09-04","underlying":"Common Stock","underlying_shares":2503050},"source":{"system":"sec-edgar","filing":"0001193125-26-384391","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000119312526384391/ownership.xml","form_type":"4"}},{"id":679726,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-20T22:18:31.000Z","date":"2026-08-20","kind":"grant","planned":false,"acquired":true,"shares":46000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest in equal monthly installments through October 31, 2026, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":46000,"derivative":{"exercise_price":3.12,"expiration_date":"2036-08-20","underlying":"Common Stock","underlying_shares":46000},"source":{"system":"sec-edgar","filing":"0001193125-26-359525","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000119312526359525/ownership.xml","form_type":"4"}},{"id":686447,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-14T20:06:09.000Z","date":"2026-08-12","kind":"grant","planned":false,"acquired":true,"shares":250956,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the performance-based portion of an option that was granted on February 3, 2026, which shares subject to this portion of the option were to become vested in full upon the completion of a successful financing transaction or a successful strategic transaction during the reporting person's continued service as Interim Chief Executive Officer or within six months thereafter. The performance conditions were deemed to have been met on August 12, 2026, as determined by the Board."}],"balance_after":941087,"derivative":{"exercise_price":1.49,"exercise_date":"2026-08-12","expiration_date":"2036-02-03","underlying":"Common Stock","underlying_shares":250956},"source":{"system":"sec-edgar","filing":"0001193125-26-352206","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723092/000119312526352206/ownership.xml","form_type":"4"}},{"id":717282,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T20:30:46.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Award of stock options to purchase Common Shares with a vesting commencement date of August 23, 2024. These options vest and become exercisable in three equal annual tranches from August 23, 2023, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation)."}],"balance_after":357461,"derivative":{"exercise_price":1.6,"expiration_date":"2033-09-22","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001193125-26-294708","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000119312526294708/ownership.xml","form_type":"4"}},{"id":717281,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T20:30:46.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":35000,"price":3.06,"value":107100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on Septemeber 24, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects sales of common stock executed in multiple transactions. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected within the ranges set forth in footnotes 3 of this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $3.00 to $3.36."}],"balance_after":38741,"source":{"system":"sec-edgar","filing":"0001193125-26-294708","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000119312526294708/ownership.xml","form_type":"4"}},{"id":717280,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T20:30:46.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":35000,"price":1.6,"value":56000.0,"ownership":{"direct":true},"balance_after":73741,"source":{"system":"sec-edgar","filing":"0001193125-26-294708","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000119312526294708/ownership.xml","form_type":"4"}},{"id":828079,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-25T21:18:44.000Z","date":"2026-03-24","kind":"grant","planned":false,"acquired":true,"shares":45867,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":45867,"derivative":{"exercise_price":1.36,"expiration_date":"2036-03-24","underlying":"Common Stock","underlying_shares":45867},"source":{"system":"sec-edgar","filing":"0001193125-26-124388","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000119312526124388/ownership.xml","form_type":"4"}},{"id":827947,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":55981,"kind":"person","name":"Wadhane Jitendra","position":1,"cik":"0001941706","reported_name":"Wadhane Jitendra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin Fin & Acct Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-25T21:17:26.000Z","date":"2026-03-24","kind":"grant","planned":false,"acquired":true,"shares":262635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of March 24, 2026 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued emmployment through the applicable vesting date."}],"balance_after":262635,"derivative":{"exercise_price":1.36,"expiration_date":"2036-03-24","underlying":"Common Stock","underlying_shares":262635},"source":{"system":"sec-edgar","filing":"0001193125-26-124380","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000119312526124380/ownership.xml","form_type":"4"}},{"id":827946,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":55981,"kind":"person","name":"Wadhane Jitendra","position":1,"cik":"0001941706","reported_name":"Wadhane Jitendra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Prin Fin & Acct Officer"}}],"security":"Common Stock","published_at":"2026-03-25T21:17:26.000Z","date":"2026-03-24","kind":"grant","planned":false,"acquired":true,"shares":109461,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest 25% on March 31, 2026, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":512882,"source":{"system":"sec-edgar","filing":"0001193125-26-124380","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000119312526124380/ownership.xml","form_type":"4"}},{"id":828103,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-25T21:09:52.000Z","date":"2026-03-24","kind":"grant","planned":false,"acquired":true,"shares":45867,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":45867,"derivative":{"exercise_price":1.36,"expiration_date":"2036-03-24","underlying":"Common Stock","underlying_shares":45867},"source":{"system":"sec-edgar","filing":"0001193125-26-124342","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1507220/000119312526124342/ownership.xml","form_type":"4"}},{"id":828346,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":36407,"kind":"person","name":"Palani Santhosh","position":1,"cik":"0002013475","reported_name":"Palani Santhosh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-25T21:04:44.000Z","date":"2026-03-24","kind":"grant","planned":false,"acquired":true,"shares":45867,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":45867,"derivative":{"exercise_price":1.36,"expiration_date":"2036-03-24","underlying":"Common Stock","underlying_shares":45867},"source":{"system":"sec-edgar","filing":"0001193125-26-124313","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2013475/000119312526124313/ownership.xml","form_type":"4"}},{"id":828457,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":56110,"kind":"person","name":"FLAVIN JOHN L","position":1,"cik":"0001126556","reported_name":"FLAVIN JOHN L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-25T17:10:59.000Z","date":"2026-03-24","kind":"grant","planned":false,"acquired":true,"shares":45867,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":45867,"derivative":{"exercise_price":1.36,"expiration_date":"2036-03-24","underlying":"Common Stock","underlying_shares":45867},"source":{"system":"sec-edgar","filing":"0001193125-26-124348","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1126556/000119312526124348/ownership.xml","form_type":"4"}},{"id":828186,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":16005,"kind":"person","name":"Lewis-Hall Freda C","position":1,"cik":"0001437909","reported_name":"Lewis-Hall Freda C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-25T17:08:25.000Z","date":"2026-03-24","kind":"grant","planned":false,"acquired":true,"shares":45867,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":45867,"derivative":{"exercise_price":1.36,"expiration_date":"2036-03-24","underlying":"Common Stock","underlying_shares":45867},"source":{"system":"sec-edgar","filing":"0001193125-26-124333","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437909/000119312526124333/ownership.xml","form_type":"4"}},{"id":828043,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":38545,"kind":"person","name":"Cline Darren S","position":1,"cik":"0001633639","reported_name":"Cline Darren S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-25T17:07:11.000Z","date":"2026-03-24","kind":"grant","planned":false,"acquired":true,"shares":45867,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":45867,"derivative":{"exercise_price":1.36,"expiration_date":"2036-03-24","underlying":"Common Stock","underlying_shares":45867},"source":{"system":"sec-edgar","filing":"0001193125-26-124325","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1633639/000119312526124325/ownership.xml","form_type":"4"}},{"id":828051,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":56009,"kind":"person","name":"HUMPHREY RACHEL","position":1,"cik":"0001579781","reported_name":"HUMPHREY RACHEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-25T17:05:57.000Z","date":"2026-03-24","kind":"grant","planned":false,"acquired":true,"shares":45867,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":45867,"derivative":{"exercise_price":1.36,"expiration_date":"2036-03-24","underlying":"Common Stock","underlying_shares":45867},"source":{"system":"sec-edgar","filing":"0001193125-26-124319","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579781/000119312526124319/ownership.xml","form_type":"4"}},{"id":828050,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":56009,"kind":"person","name":"HUMPHREY RACHEL","position":1,"cik":"0001579781","reported_name":"HUMPHREY RACHEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-25T16:30:11.000Z","date":"2025-04-21","kind":"sale","planned":true,"acquired":false,"shares":13896,"price":1.0335,"value":14361.516,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects sales of common stock executed in multiple transactions. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected within the ranges set forth in footnotes 3 through 4 of this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades in prices ranging from $0.97 to $1.09."}],"balance_after":81309,"source":{"system":"sec-edgar","filing":"0000905148-26-001434","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1579781/000090514826001434/form4.xml","form_type":"4"}},{"id":828049,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":56009,"kind":"person","name":"HUMPHREY RACHEL","position":1,"cik":"0001579781","reported_name":"HUMPHREY RACHEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-25T16:30:11.000Z","date":"2025-04-17","kind":"sale","planned":true,"acquired":false,"shares":200,"price":0.97,"value":194.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2024."}],"balance_after":95205,"source":{"system":"sec-edgar","filing":"0000905148-26-001434","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1579781/000090514826001434/form4.xml","form_type":"4"}},{"id":828048,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":56009,"kind":"person","name":"HUMPHREY RACHEL","position":1,"cik":"0001579781","reported_name":"HUMPHREY RACHEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-25T16:30:11.000Z","date":"2025-04-14","kind":"sale","planned":true,"acquired":false,"shares":1400,"price":0.9727,"value":1361.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects sales of common stock executed in multiple transactions. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected within the ranges set forth in footnotes 3 through 4 of this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $0.97 to $0.98."}],"balance_after":95405,"source":{"system":"sec-edgar","filing":"0000905148-26-001434","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579781/000090514826001434/form4.xml","form_type":"4"}},{"id":917274,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-06T01:37:38.000Z","date":"2026-02-03","kind":"grant","planned":false,"acquired":true,"shares":690131,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest in 12 equal monthly installments, commencing on the grant date and subject to the reporting person's continued service as Interim Chief Executive Officer through the applicable vesting date."}],"balance_after":690131,"derivative":{"exercise_price":1.49,"expiration_date":"2036-02-03","underlying":"Common Stock","underlying_shares":690131},"source":{"system":"sec-edgar","filing":"0001193125-26-039951","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723092/000119312526039951/ownership.xml","form_type":"4"}},{"id":1182731,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T13:05:43.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":36979,"price":0.98,"value":36239.42,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":36979,"derivative":{"exercise_price":0.98,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":36979},"source":{"system":"sec-edgar","filing":"0000950170-25-048903","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1507220/000095017025048903/ownership.xml","form_type":"4"}},{"id":1182386,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":55981,"kind":"person","name":"Wadhane Jitendra","position":1,"cik":"0001941706","reported_name":"Wadhane Jitendra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T13:04:17.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":263782,"price":0.98,"value":258506.36,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of March 31,2025 and the remainder vesting in 36 equal monthly instalments thereafter subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":263782,"derivative":{"exercise_price":0.98,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":263782},"source":{"system":"sec-edgar","filing":"0000950170-25-048902","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017025048902/ownership.xml","form_type":"4"}},{"id":1182682,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T13:00:15.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":36979,"price":0.98,"value":36239.42,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":36979,"derivative":{"exercise_price":0.98,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":36979},"source":{"system":"sec-edgar","filing":"0000950170-25-048898","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000095017025048898/ownership.xml","form_type":"4"}},{"id":1184014,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":36407,"kind":"person","name":"Palani Santhosh","position":1,"cik":"0002013475","reported_name":"Palani Santhosh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T12:58:35.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":36979,"price":0.98,"value":36239.42,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":36979,"derivative":{"exercise_price":0.98,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":36979},"source":{"system":"sec-edgar","filing":"0000950170-25-048895","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2013475/000095017025048895/ownership.xml","form_type":"4"}},{"id":1182422,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T12:57:37.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":36979,"price":0.98,"value":36239.42,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":36979,"derivative":{"exercise_price":0.98,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":36979},"source":{"system":"sec-edgar","filing":"0000950170-25-048894","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723092/000095017025048894/ownership.xml","form_type":"4"}},{"id":1182385,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":35405,"kind":"person","name":"Connealy Pamela Ann","position":1,"cik":"0001796310","reported_name":"Connealy Pamela Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T12:56:28.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":414163,"price":0.98,"value":405879.74,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of March 31, 2025 and the remainder vesting in 36 equal monthly installments thereafter subject to the reporting person's continued emmployment through the applicable vesting date."}],"balance_after":414163,"derivative":{"exercise_price":0.98,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":414163},"source":{"system":"sec-edgar","filing":"0000950170-25-048893","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017025048893/ownership.xml","form_type":"4"}},{"id":1182392,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President ,CEO & CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T09:06:50.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":918308,"price":0.98,"value":899941.84,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of March 31,2025 and the remainder vesting in 36 equal monthly instalments thereafter subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":918308,"derivative":{"exercise_price":0.98,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":918308},"source":{"system":"sec-edgar","filing":"0000950170-25-048905","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000095017025048905/ownership.xml","form_type":"4"}},{"id":1182582,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":56009,"kind":"person","name":"HUMPHREY RACHEL","position":1,"cik":"0001579781","reported_name":"HUMPHREY RACHEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock  Option  (Right to  Buy)","published_at":"2025-04-02T09:03:25.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":36979,"price":0.98,"value":36239.42,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":36979,"derivative":{"exercise_price":0.98,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":36979},"source":{"system":"sec-edgar","filing":"0000950170-25-048901","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579781/000095017025048901/ownership.xml","form_type":"4"}},{"id":1183203,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":16005,"kind":"person","name":"Lewis-Hall Freda C","position":1,"cik":"0001437909","reported_name":"Lewis-Hall Freda C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock  Option  (Right to  Buy)","published_at":"2025-04-02T09:02:32.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":36979,"price":0.98,"value":36239.42,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":36979,"derivative":{"exercise_price":0.98,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":36979},"source":{"system":"sec-edgar","filing":"0000950170-25-048900","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437909/000095017025048900/ownership.xml","form_type":"4"}},{"id":1182501,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":38545,"kind":"person","name":"Cline Darren S","position":1,"cik":"0001633639","reported_name":"Cline Darren S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T09:01:38.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":36979,"price":0.98,"value":36239.42,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":36979,"derivative":{"exercise_price":0.98,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":36979},"source":{"system":"sec-edgar","filing":"0000950170-25-048899","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1633639/000095017025048899/ownership.xml","form_type":"4"}},{"id":1184239,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":56110,"kind":"person","name":"FLAVIN JOHN L","position":1,"cik":"0001126556","reported_name":"FLAVIN JOHN L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T08:55:19.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":36979,"price":0.98,"value":36239.42,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":36979,"derivative":{"exercise_price":0.98,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":36979},"source":{"system":"sec-edgar","filing":"0000950170-25-048892","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1126556/000095017025048892/ownership.xml","form_type":"4"}},{"id":1322517,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":35405,"kind":"person","name":"Connealy Pamela Ann","position":1,"cik":"0001796310","reported_name":"Connealy Pamela Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-23T21:30:23.000Z","date":"2024-12-23","kind":"grant","planned":false,"acquired":true,"shares":310000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest in full on December 23, 2025, subject to the Reporting Person's continued employment through the vesting date."}],"balance_after":310000,"derivative":{"exercise_price":1.67,"expiration_date":"2034-12-23","underlying":"Common Stock","underlying_shares":310000},"source":{"system":"sec-edgar","filing":"0000950170-24-139608","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024139608/ownership.xml","form_type":"4"}},{"id":1322516,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":55981,"kind":"person","name":"Wadhane Jitendra","position":1,"cik":"0001941706","reported_name":"Wadhane Jitendra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-23T21:26:34.000Z","date":"2024-12-23","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest in full on December 23, 2025, subject to the Reporting Person's continued employment through the vesting date."}],"balance_after":150000,"derivative":{"exercise_price":1.67,"expiration_date":"2034-12-23","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000950170-24-139598","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024139598/ownership.xml","form_type":"4"}},{"id":1322532,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-23T16:33:32.000Z","date":"2024-12-23","kind":"grant","planned":false,"acquired":true,"shares":1135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest in full on December 23, 2025, subject to the Reporting Person's continued employment through the vesting date."}],"balance_after":1135000,"derivative":{"exercise_price":1.67,"expiration_date":"2034-12-23","underlying":"Common Stock","underlying_shares":1135000},"source":{"system":"sec-edgar","filing":"0000950170-24-139616","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000095017024139616/ownership.xml","form_type":"4"}},{"id":1348785,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":35405,"kind":"person","name":"Connealy Pamela Ann","position":1,"cik":"0001796310","reported_name":"Connealy Pamela Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & COO"}}],"security":"Common Stock","published_at":"2024-11-27T22:09:59.000Z","date":"2024-11-26","kind":"purchase","planned":false,"acquired":true,"shares":83400,"price":1.96,"value":163464.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted-average price.These shares were purchased in multiple transactions at prices ranging from $1.93 to $1.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."}],"balance_after":1199143,"source":{"system":"sec-edgar","filing":"0000950170-24-131606","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024131606/ownership.xml","form_type":"4"}},{"id":1348784,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":35405,"kind":"person","name":"Connealy Pamela Ann","position":1,"cik":"0001796310","reported_name":"Connealy Pamela Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & COO"}}],"security":"Common Stock","published_at":"2024-11-27T22:09:59.000Z","date":"2024-11-26","kind":"purchase","planned":false,"acquired":true,"shares":5450,"price":2,"value":10900.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held directly by the Personal Def Ben Pln Trust, a revocable trust for which the Reporting Person and their spouse are the trustees."}],"balance_after":1115743,"source":{"system":"sec-edgar","filing":"0000950170-24-131606","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024131606/ownership.xml","form_type":"4"}},{"id":1484549,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":31181,"kind":"person","name":"Metzger Michael A","position":1,"cik":"0001507220","reported_name":"Metzger Michael A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-10T21:31:39.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":70683,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in three equal annual installments beginning on the first anniversary of June 10, 2024, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":70683,"derivative":{"exercise_price":3.97,"expiration_date":"2034-06-10","underlying":"Common Stock","underlying_shares":70683},"source":{"system":"sec-edgar","filing":"0000950170-24-071438","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1507220/000095017024071438/ownership.xml","form_type":"4"}},{"id":1487227,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":36407,"kind":"person","name":"Palani Santhosh","position":1,"cik":"0002013475","reported_name":"Palani Santhosh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T21:00:32.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0000950170-24-070833","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2013475/000095017024070833/ownership.xml","form_type":"4"}},{"id":1558177,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":35405,"kind":"person","name":"Connealy Pamela Ann","position":1,"cik":"0001796310","reported_name":"Connealy Pamela Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & COO"}}],"security":"Common Stock","published_at":"2024-03-28T20:33:47.000Z","date":"2024-03-26","kind":"grant","planned":false,"acquired":true,"shares":328710,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest 25% on the first anniversary of March 26, 2024, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":1110293,"source":{"system":"sec-edgar","filing":"0000950170-24-038108","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024038108/ownership.xml","form_type":"4"}},{"id":1558215,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-28T20:32:39.000Z","date":"2024-03-26","kind":"grant","planned":false,"acquired":true,"shares":38741,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":38741,"source":{"system":"sec-edgar","filing":"0000950170-24-038102","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000095017024038102/ownership.xml","form_type":"4"}},{"id":1558183,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-28T20:32:03.000Z","date":"2024-03-26","kind":"grant","planned":false,"acquired":true,"shares":44024,"price":3.83,"value":168611.92,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":44024,"derivative":{"exercise_price":3.83,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":44024},"source":{"system":"sec-edgar","filing":"0000950170-24-038098","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723092/000095017024038098/ownership.xml","form_type":"4"}},{"id":1558175,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":55981,"kind":"person","name":"Wadhane Jitendra","position":1,"cik":"0001941706","reported_name":"Wadhane Jitendra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2024-03-28T20:31:43.000Z","date":"2024-03-26","kind":"grant","planned":false,"acquired":true,"shares":131484,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest 25% on the first anniversary of March 26, 2024, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":398421,"source":{"system":"sec-edgar","filing":"0000950170-24-038097","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017024038097/ownership.xml","form_type":"4"}},{"id":1558176,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-28T16:33:30.000Z","date":"2024-03-26","kind":"grant","planned":false,"acquired":true,"shares":1071242,"price":3.83,"value":4102856.86,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of March 26, 2024 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":1071242,"derivative":{"exercise_price":3.83,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":1071242},"source":{"system":"sec-edgar","filing":"0000950170-24-038106","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000095017024038106/ownership.xml","form_type":"4"}},{"id":1558688,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":56110,"kind":"person","name":"FLAVIN JOHN L","position":1,"cik":"0001126556","reported_name":"FLAVIN JOHN L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-28T16:33:18.000Z","date":"2024-03-26","kind":"grant","planned":false,"acquired":true,"shares":35219,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":413015,"source":{"system":"sec-edgar","filing":"0000950170-24-038104","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1126556/000095017024038104/ownership.xml","form_type":"4"}},{"id":1558203,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":38545,"kind":"person","name":"Cline Darren S","position":1,"cik":"0001633639","reported_name":"Cline Darren S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-28T16:33:15.000Z","date":"2024-03-26","kind":"grant","planned":false,"acquired":true,"shares":35219,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":251405,"source":{"system":"sec-edgar","filing":"0000950170-24-038105","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1633639/000095017024038105/ownership.xml","form_type":"4"}},{"id":1558330,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":16005,"kind":"person","name":"Lewis-Hall Freda C","position":1,"cik":"0001437909","reported_name":"Lewis-Hall Freda C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-28T16:32:58.000Z","date":"2024-03-26","kind":"grant","planned":false,"acquired":true,"shares":35219,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":241405,"source":{"system":"sec-edgar","filing":"0000950170-24-038103","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437909/000095017024038103/ownership.xml","form_type":"4"}},{"id":1558209,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":56009,"kind":"person","name":"HUMPHREY RACHEL","position":1,"cik":"0001579781","reported_name":"HUMPHREY RACHEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-28T16:32:21.000Z","date":"2024-03-26","kind":"grant","planned":false,"acquired":true,"shares":38741,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":96805,"source":{"system":"sec-edgar","filing":"0000950170-24-038099","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579781/000095017024038099/ownership.xml","form_type":"4"}},{"id":1579095,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":36407,"kind":"person","name":"Palani Santhosh","position":1,"cik":"0002013475","reported_name":"Palani Santhosh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-13T20:54:35.000Z","date":"2024-03-12","kind":"grant","planned":false,"acquired":true,"shares":69760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in three equal annual installments beginning on the first anniversary of March 12, 2024, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":69760,"derivative":{"exercise_price":5.7,"expiration_date":"2034-03-12","underlying":"Common Stock","underlying_shares":69760},"source":{"system":"sec-edgar","filing":"0000950170-24-030865","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2013475/000095017024030865/ownership.xml","form_type":"4"}},{"id":1698099,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":95753,"kind":"person","name":"Kobayashi Ken","position":1,"cik":"0002003383","reported_name":"Kobayashi Ken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-29T16:33:36.000Z","date":"2023-12-29","kind":"grant","planned":false,"acquired":true,"shares":110878,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option will vest upon the achievement of certain clinical milestones related to data disclosure for PYX-201."}],"balance_after":110878,"derivative":{"exercise_price":1.8,"expiration_date":"2033-12-29","underlying":"Common Stock","underlying_shares":110878},"source":{"system":"sec-edgar","filing":"0001209191-23-060006","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2003383/000120919123060006/doc4.xml","form_type":"4"}},{"id":1698098,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":95753,"kind":"person","name":"Kobayashi Ken","position":1,"cik":"0002003383","reported_name":"Kobayashi Ken","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-29T16:33:36.000Z","date":"2023-12-29","kind":"grant","planned":false,"acquired":true,"shares":443514,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest over four years, with 25% vesting on November 27, 2024 and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment through the applicable vesting dates."}],"balance_after":443514,"derivative":{"exercise_price":1.8,"expiration_date":"2033-12-29","underlying":"Common Stock","underlying_shares":443514},"source":{"system":"sec-edgar","filing":"0001209191-23-060006","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2003383/000120919123060006/doc4.xml","form_type":"4"}},{"id":1726436,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":35405,"kind":"person","name":"Connealy Pamela Ann","position":1,"cik":"0001796310","reported_name":"Connealy Pamela Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2023-11-30T21:15:23.000Z","date":"2023-11-29","kind":"tax_withholding","planned":false,"acquired":false,"shares":36949,"price":1.4,"value":51728.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to cover taxes due upon the vesting of certain restricted stock units."}],"balance_after":781583,"source":{"system":"sec-edgar","filing":"0001209191-23-056969","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000120919123056969/doc4.xml","form_type":"4"}},{"id":1735958,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":55981,"kind":"person","name":"Wadhane Jitendra","position":1,"cik":"0001941706","reported_name":"Wadhane Jitendra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-11-17T21:16:45.000Z","date":"2023-11-15","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest in full on November 14, 2024, subject to the Reporting Person's continued employment through the vesting date."}],"balance_after":266937,"source":{"system":"sec-edgar","filing":"0001209191-23-055744","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000120919123055744/doc4.xml","form_type":"4"}},{"id":1771978,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":35405,"kind":"person","name":"Connealy Pamela Ann","position":1,"cik":"0001796310","reported_name":"Connealy Pamela Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2023-09-28T20:32:03.000Z","date":"2023-09-28","kind":"purchase","planned":false,"acquired":true,"shares":8000,"price":1.87,"value":14960.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person purchased all 8,000 shares of common stock in the open market at a price of $1.87 per share."}],"balance_after":818532,"source":{"system":"sec-edgar","filing":"0001209191-23-050734","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000120919123050734/doc4.xml","form_type":"4"}},{"id":1772495,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":55981,"kind":"person","name":"Wadhane Jitendra","position":1,"cik":"0001941706","reported_name":"Wadhane Jitendra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-09-27T22:37:45.000Z","date":"2023-09-27","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":1.87,"value":4675.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person purchased all 2,500 shares of common stock in the open market at a price of $1.87 per share."}],"balance_after":226937,"source":{"system":"sec-edgar","filing":"0001209191-23-050686","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000120919123050686/doc4.xml","form_type":"4"}},{"id":1772494,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":35405,"kind":"person","name":"Connealy Pamela Ann","position":1,"cik":"0001796310","reported_name":"Connealy Pamela Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2023-09-27T22:36:38.000Z","date":"2023-09-27","kind":"purchase","planned":false,"acquired":true,"shares":6426,"price":1.8468,"value":11867.5368,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of common stock purchased by the Reporting Person in open market transactions. The range of purchase prices on the transaction date was $1.78 to $1.87 per share. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each price."}],"balance_after":810532,"source":{"system":"sec-edgar","filing":"0001209191-23-050685","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000120919123050685/doc4.xml","form_type":"4"}},{"id":1773089,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-26T23:04:57.000Z","date":"2023-09-22","kind":"grant","planned":false,"acquired":true,"shares":392461,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These stock options vest in three equal annual installments beginning on the first anniversary of August 23, 2023, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":392461,"derivative":{"exercise_price":1.6,"expiration_date":"2033-09-22","underlying":"Common Stock","underlying_shares":392461},"source":{"system":"sec-edgar","filing":"0001209191-23-050613","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000120919123050613/doc4.xml","form_type":"4"}},{"id":1773743,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":55981,"kind":"person","name":"Wadhane Jitendra","position":1,"cik":"0001941706","reported_name":"Wadhane Jitendra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-09-25T21:05:30.000Z","date":"2023-09-25","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":1.77,"value":8850.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person purchased all 5,000 shares of common stock in the open market at a price of $1.77 per share."}],"balance_after":224437,"source":{"system":"sec-edgar","filing":"0001209191-23-050495","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000120919123050495/doc4.xml","form_type":"4"}},{"id":1773742,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":35405,"kind":"person","name":"Connealy Pamela Ann","position":1,"cik":"0001796310","reported_name":"Connealy Pamela Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2023-09-25T21:04:12.000Z","date":"2023-09-25","kind":"purchase","planned":false,"acquired":true,"shares":12000,"price":1.6703,"value":20043.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of common stock purchased by the Reporting Person in open market transactions. The range of purchase prices on the transaction date was $1.615 to $1.70 per share. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each price."}],"balance_after":804106,"source":{"system":"sec-edgar","filing":"0001209191-23-050492","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000120919123050492/doc4.xml","form_type":"4"}},{"id":1774449,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":55981,"kind":"person","name":"Wadhane Jitendra","position":1,"cik":"0001941706","reported_name":"Wadhane Jitendra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-09-22T23:35:51.000Z","date":"2023-09-22","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":1.7397,"value":4349.25,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person purchased all 2,500 shares of common stock in the open market at a price of $1.7397 per share."}],"balance_after":219437,"source":{"system":"sec-edgar","filing":"0001209191-23-050433","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000120919123050433/doc4.xml","form_type":"4"}},{"id":1774448,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":35405,"kind":"person","name":"Connealy Pamela Ann","position":1,"cik":"0001796310","reported_name":"Connealy Pamela Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2023-09-22T23:34:33.000Z","date":"2023-09-22","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":1.739,"value":8695.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person purchased all 5,000 shares of common stock in the open market at a price of $1.739 per share."}],"balance_after":792106,"source":{"system":"sec-edgar","filing":"0001209191-23-050432","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000120919123050432/doc4.xml","form_type":"4"}},{"id":1778603,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-09-18T19:03:40.000Z","date":"2023-09-18","kind":"sale","planned":false,"acquired":false,"shares":8541,"price":2.1,"value":17936.1,"ownership":{"direct":true},"balance_after":2403882,"source":{"system":"sec-edgar","filing":"0001209191-23-049826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000120919123049826/doc4.xml","form_type":"4"}},{"id":1778602,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-09-18T19:03:40.000Z","date":"2023-09-14","kind":"sale","planned":false,"acquired":false,"shares":100,"price":2.25,"value":225.0,"ownership":{"direct":true},"balance_after":2412423,"source":{"system":"sec-edgar","filing":"0001209191-23-049826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000120919123049826/doc4.xml","form_type":"4"}},{"id":1781705,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-09-13T20:16:19.000Z","date":"2023-09-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":184742,"price":2.13,"value":393500.46,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares withheld to cover taxes due upon the vesting of certain restricted stock units."}],"balance_after":2412523,"source":{"system":"sec-edgar","filing":"0001209191-23-049366","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000120919123049366/doc4.xml","form_type":"4"}},{"id":1781704,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-09-13T20:16:19.000Z","date":"2023-09-13","kind":"sale","planned":false,"acquired":false,"shares":3000,"price":2.2719,"value":6815.7,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected within the ranges set forth in footnotes 2 through 4 of this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades in prices ranging from $2.25 to $2.34."}],"balance_after":2597265,"source":{"system":"sec-edgar","filing":"0001209191-23-049366","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000120919123049366/doc4.xml","form_type":"4"}},{"id":1781703,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-09-13T20:16:19.000Z","date":"2023-09-12","kind":"sale","planned":false,"acquired":false,"shares":4917,"price":2.2516,"value":11071.1172,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected within the ranges set forth in footnotes 2 through 4 of this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $2.21 to $2.30."}],"balance_after":2600265,"source":{"system":"sec-edgar","filing":"0001209191-23-049366","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000120919123049366/doc4.xml","form_type":"4"}},{"id":1781702,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-09-13T20:16:19.000Z","date":"2023-09-11","kind":"sale","planned":false,"acquired":false,"shares":20000,"price":2.2707,"value":45414.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected within the ranges set forth in footnotes 2 through 4 of this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $2.13 to $2.36."}],"balance_after":2605182,"source":{"system":"sec-edgar","filing":"0001209191-23-049366","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000120919123049366/doc4.xml","form_type":"4"}},{"id":1784424,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":35405,"kind":"person","name":"Connealy Pamela Ann","position":1,"cik":"0001796310","reported_name":"Connealy Pamela Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2023-09-08T21:02:00.000Z","date":"2023-09-07","kind":"grant","planned":false,"acquired":true,"shares":187793,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that are fully vested."}],"balance_after":782106,"source":{"system":"sec-edgar","filing":"0001209191-23-048819","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000120919123048819/doc4.xml","form_type":"4"}},{"id":1784423,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":55981,"kind":"person","name":"Wadhane Jitendra","position":1,"cik":"0001941706","reported_name":"Wadhane Jitendra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-09-08T21:01:18.000Z","date":"2023-09-07","kind":"grant","planned":false,"acquired":true,"shares":93896,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that are fully vested."}],"balance_after":211937,"source":{"system":"sec-edgar","filing":"0001209191-23-048816","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000120919123048816/doc4.xml","form_type":"4"}},{"id":1784427,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-09-08T17:00:23.000Z","date":"2023-09-07","kind":"grant","planned":false,"acquired":true,"shares":469483,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that are fully vested."}],"balance_after":2625182,"source":{"system":"sec-edgar","filing":"0001209191-23-048814","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000120919123048814/doc4.xml","form_type":"4"}},{"id":1796041,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2023-08-25T21:30:50.000Z","date":"2023-08-23","kind":"grant","planned":false,"acquired":true,"shares":17250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 23, 2023, the Issuer, Ascent Merger Sub Corp., a wholly-owned subsidiary of the Issuer, or the Merger Sub, and Apexigen, Inc., or Apexigen, entered into a definitive agreement for the Issuer to acquire Apexigen, or the Merger Agreement. Under the terms of the Merger Agreement, the reporting person's options to purchase shares of Apexigen Common Stock, or the Apexigen Options, that were outstanding immediately prior to the effective time of the merger were assumed by the Issuer and converted into options to acquire, on substantially similar terms and conditions, the number of shares of the Issuer Common Stock determined by multiplying the number of shares subject to the Apexigen Options by 0.1725, or the Exchange Ratio, shares of the Issuer Common Stock, rounded down to the nearest whole share, with an exercise price per share equal to the exercise price per share of such Apexigen Option divided by the Exchange Ratio, rounded up to the nearest whole cent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vested in full immediately prior to the closing of the merger described in footnote 2."}],"balance_after":17250,"derivative":{"exercise_price":15.37,"expiration_date":"2032-09-29","underlying":"Common Stock","underlying_shares":17250},"source":{"system":"sec-edgar","filing":"0001209191-23-047384","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000120919123047384/doc4.xml","form_type":"4"}},{"id":1796040,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2023-08-25T21:30:50.000Z","date":"2023-08-23","kind":"grant","planned":false,"acquired":true,"shares":3534,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 23, 2023, the Issuer, Ascent Merger Sub Corp., a wholly-owned subsidiary of the Issuer, or the Merger Sub, and Apexigen, Inc., or Apexigen, entered into a definitive agreement for the Issuer to acquire Apexigen, or the Merger Agreement. Under the terms of the Merger Agreement, the reporting person's options to purchase shares of Apexigen Common Stock, or the Apexigen Options, that were outstanding immediately prior to the effective time of the merger were assumed by the Issuer and converted into options to acquire, on substantially similar terms and conditions, the number of shares of the Issuer Common Stock determined by multiplying the number of shares subject to the Apexigen Options by 0.1725, or the Exchange Ratio, shares of the Issuer Common Stock, rounded down to the nearest whole share, with an exercise price per share equal to the exercise price per share of such Apexigen Option divided by the Exchange Ratio, rounded up to the nearest whole cent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vested in full immediately prior to the closing of the merger described in footnote 2."}],"balance_after":3534,"derivative":{"exercise_price":26.61,"expiration_date":"2031-02-12","underlying":"Common Stock","underlying_shares":3534},"source":{"system":"sec-edgar","filing":"0001209191-23-047384","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000120919123047384/doc4.xml","form_type":"4"}},{"id":1796039,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":21169,"kind":"person","name":"Dupont Jakob","position":1,"cik":"0001553335","reported_name":"Dupont Jakob","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2023-08-25T21:30:50.000Z","date":"2023-08-23","kind":"grant","planned":false,"acquired":true,"shares":5879,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 23, 2023, the Issuer, Ascent Merger Sub Corp., a wholly-owned subsidiary of the Issuer, or the Merger Sub, and Apexigen, Inc., or Apexigen, entered into a definitive agreement for the Issuer to acquire Apexigen, or the Merger Agreement. Under the terms of the Merger Agreement, the reporting person's options to purchase shares of Apexigen Common Stock, or the Apexigen Options, that were outstanding immediately prior to the effective time of the merger were assumed by the Issuer and converted into options to acquire, on substantially similar terms and conditions, the number of shares of the Issuer Common Stock determined by multiplying the number of shares subject to the Apexigen Options by 0.1725, or the Exchange Ratio, shares of the Issuer Common Stock, rounded down to the nearest whole share, with an exercise price per share equal to the exercise price per share of such Apexigen Option divided by the Exchange Ratio, rounded up to the nearest whole cent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vested in full immediately prior to the closing of the merger described in footnote 2."}],"balance_after":5879,"derivative":{"exercise_price":26.61,"expiration_date":"2030-09-01","underlying":"Common Stock","underlying_shares":5879},"source":{"system":"sec-edgar","filing":"0001209191-23-047384","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553335/000120919123047384/doc4.xml","form_type":"4"}},{"id":1936455,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":35405,"kind":"person","name":"Connealy Pamela Ann","position":1,"cik":"0001796310","reported_name":"Yanchik Connealy Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Stock Option (Right to buy)","published_at":"2023-03-28T20:47:02.000Z","date":"2023-03-24","kind":"grant","planned":false,"acquired":true,"shares":10304,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These stock options vested 25% on the first anniversary of the closing of the Issuer's initial public offering, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":10304,"derivative":{"exercise_price":2.21,"expiration_date":"2031-09-14","underlying":"Common Stock","underlying_shares":10304},"source":{"system":"sec-edgar","filing":"0001209191-23-021413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000120919123021413/doc4.xml","form_type":"4"}},{"id":1936454,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":35405,"kind":"person","name":"Connealy Pamela Ann","position":1,"cik":"0001796310","reported_name":"Yanchik Connealy Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Stock Option (Right to buy)","published_at":"2023-03-28T20:47:02.000Z","date":"2023-03-24","kind":"grant","planned":false,"acquired":true,"shares":322265,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options vested 25% on the first anniversary of the July 31, 2021 grant date, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":322265,"derivative":{"exercise_price":2.21,"expiration_date":"2031-07-30","underlying":"Common Stock","underlying_shares":322265},"source":{"system":"sec-edgar","filing":"0001209191-23-021413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000120919123021413/doc4.xml","form_type":"4"}},{"id":1936453,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":35405,"kind":"person","name":"Connealy Pamela Ann","position":1,"cik":"0001796310","reported_name":"Yanchik Connealy Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Stock Option (Right to buy)","published_at":"2023-03-28T20:47:02.000Z","date":"2023-03-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10304,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These stock options vested 25% on the first anniversary of the closing of the Issuer's initial public offering, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.71,"expiration_date":"2031-09-14","underlying":"Common Stock","underlying_shares":10304},"source":{"system":"sec-edgar","filing":"0001209191-23-021413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000120919123021413/doc4.xml","form_type":"4"}},{"id":1936452,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":35405,"kind":"person","name":"Connealy Pamela Ann","position":1,"cik":"0001796310","reported_name":"Yanchik Connealy Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Stock Option (Right to buy)","published_at":"2023-03-28T20:47:02.000Z","date":"2023-03-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":322265,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options vested 25% on the first anniversary of the July 31, 2021 grant date, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.71,"expiration_date":"2031-07-30","underlying":"Common Stock","underlying_shares":322265},"source":{"system":"sec-edgar","filing":"0001209191-23-021413","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000120919123021413/doc4.xml","form_type":"4"}},{"id":1936451,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":35405,"kind":"person","name":"Connealy Pamela Ann","position":1,"cik":"0001796310","reported_name":"Yanchik Connealy Pamela","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2023-03-28T20:47:02.000Z","date":"2023-03-24","kind":"grant","planned":false,"acquired":true,"shares":209803,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest 25% on March 24, 2024, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":594313,"source":{"system":"sec-edgar","filing":"0001209191-23-021413","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000120919123021413/doc4.xml","form_type":"4"}},{"id":1936445,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":55981,"kind":"person","name":"Wadhane Jitendra","position":1,"cik":"0001941706","reported_name":"Wadhane Jitendra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2023-03-28T20:45:11.000Z","date":"2023-03-24","kind":"grant","planned":false,"acquired":true,"shares":157257,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These stock options vested 25% on August 23, 2022, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":157257,"derivative":{"exercise_price":2.21,"expiration_date":"2031-07-30","underlying":"Common Stock","underlying_shares":157257},"source":{"system":"sec-edgar","filing":"0001209191-23-021411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000120919123021411/doc4.xml","form_type":"4"}},{"id":1936444,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":55981,"kind":"person","name":"Wadhane Jitendra","position":1,"cik":"0001941706","reported_name":"Wadhane Jitendra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2023-03-28T20:45:11.000Z","date":"2023-03-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":157257,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These stock options vested 25% on August 23, 2022, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.71,"expiration_date":"2031-07-30","underlying":"Common Stock","underlying_shares":157257},"source":{"system":"sec-edgar","filing":"0001209191-23-021411","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000120919123021411/doc4.xml","form_type":"4"}},{"id":1936443,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":55981,"kind":"person","name":"Wadhane Jitendra","position":1,"cik":"0001941706","reported_name":"Wadhane Jitendra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-03-28T20:45:11.000Z","date":"2023-03-24","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock units that vest 25% on August 3, 2023, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":88648,"source":{"system":"sec-edgar","filing":"0001209191-23-021411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000120919123021411/doc4.xml","form_type":"4"}},{"id":1936442,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":55981,"kind":"person","name":"Wadhane Jitendra","position":1,"cik":"0001941706","reported_name":"Wadhane Jitendra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2023-03-28T20:45:11.000Z","date":"2023-03-24","kind":"grant","planned":false,"acquired":true,"shares":29393,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest 25% on March 24, 2024, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":118041,"source":{"system":"sec-edgar","filing":"0001209191-23-021411","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782223/000120919123021411/doc4.xml","form_type":"4"}},{"id":1936470,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":23216,"kind":"person","name":"Civik Thomas","position":1,"cik":"0001723092","reported_name":"Civik Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-28T20:41:02.000Z","date":"2023-03-24","kind":"grant","planned":false,"acquired":true,"shares":139355,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":206186,"source":{"system":"sec-edgar","filing":"0001209191-23-021404","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1723092/000120919123021404/doc4.xml","form_type":"4"}},{"id":1936450,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2023-03-28T16:48:11.000Z","date":"2023-03-24","kind":"grant","planned":false,"acquired":true,"shares":61825,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These stock options vested 25% on the first anniversary of the closing of the Issuer's initial public offering, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":61825,"derivative":{"exercise_price":2.21,"expiration_date":"2031-09-14","underlying":"Common Stock","underlying_shares":61825},"source":{"system":"sec-edgar","filing":"0001209191-23-021415","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000120919123021415/doc4.xml","form_type":"4"}},{"id":1936449,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2023-03-28T16:48:11.000Z","date":"2023-03-24","kind":"grant","planned":false,"acquired":true,"shares":990461,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options vest in 48 substantially-equal monthly installments beginning January 2, 2020, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":990461,"derivative":{"exercise_price":2.21,"expiration_date":"2031-03-30","underlying":"Common Stock","underlying_shares":990461},"source":{"system":"sec-edgar","filing":"0001209191-23-021415","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000120919123021415/doc4.xml","form_type":"4"}},{"id":1936448,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2023-03-28T16:48:11.000Z","date":"2023-03-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":61825,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These stock options vested 25% on the first anniversary of the closing of the Issuer's initial public offering, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.71,"expiration_date":"2031-09-14","underlying":"Common Stock","underlying_shares":61825},"source":{"system":"sec-edgar","filing":"0001209191-23-021415","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000120919123021415/doc4.xml","form_type":"4"}},{"id":1936447,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2023-03-28T16:48:11.000Z","date":"2023-03-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":990461,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options vest in 48 substantially-equal monthly installments beginning January 2, 2020, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":5.34,"expiration_date":"2031-03-30","underlying":"Common Stock","underlying_shares":990461},"source":{"system":"sec-edgar","filing":"0001209191-23-021415","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000120919123021415/doc4.xml","form_type":"4"}},{"id":1936446,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-03-28T16:48:11.000Z","date":"2023-03-24","kind":"grant","planned":false,"acquired":true,"shares":703379,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest 25% on March 24, 2024, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":2155699,"source":{"system":"sec-edgar","filing":"0001209191-23-021415","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000120919123021415/doc4.xml","form_type":"4"}},{"id":1937040,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":115093,"kind":"person","name":"Feingold Jay","position":1,"cik":"0001885838","reported_name":"Feingold Jay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2023-03-28T16:45:54.000Z","date":"2023-03-24","kind":"grant","planned":false,"acquired":true,"shares":17517,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These stock options vested 25% on the first anniversary of the closing of the Issuer's initial public offering, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":17517,"derivative":{"exercise_price":2.21,"expiration_date":"2031-09-14","underlying":"Common Stock","underlying_shares":17517},"source":{"system":"sec-edgar","filing":"0001209191-23-021412","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1885838/000120919123021412/doc4.xml","form_type":"4"}},{"id":1937039,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":115093,"kind":"person","name":"Feingold Jay","position":1,"cik":"0001885838","reported_name":"Feingold Jay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2023-03-28T16:45:54.000Z","date":"2023-03-24","kind":"grant","planned":false,"acquired":true,"shares":157257,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options vested 25% on the first anniversary of the September 13, 2021 grant date, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":157257,"derivative":{"exercise_price":2.21,"expiration_date":"2031-09-12","underlying":"Common Stock","underlying_shares":157257},"source":{"system":"sec-edgar","filing":"0001209191-23-021412","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1885838/000120919123021412/doc4.xml","form_type":"4"}},{"id":1937038,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":115093,"kind":"person","name":"Feingold Jay","position":1,"cik":"0001885838","reported_name":"Feingold Jay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2023-03-28T16:45:54.000Z","date":"2023-03-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17517,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These stock options vested 25% on the first anniversary of the closing of the Issuer's initial public offering, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.71,"expiration_date":"2031-09-14","underlying":"Common Stock","underlying_shares":17517},"source":{"system":"sec-edgar","filing":"0001209191-23-021412","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885838/000120919123021412/doc4.xml","form_type":"4"}},{"id":1937037,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":115093,"kind":"person","name":"Feingold Jay","position":1,"cik":"0001885838","reported_name":"Feingold Jay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2023-03-28T16:45:54.000Z","date":"2023-03-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":157257,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options vested 25% on the first anniversary of the September 13, 2021 grant date, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.71,"expiration_date":"2031-09-12","underlying":"Common Stock","underlying_shares":157257},"source":{"system":"sec-edgar","filing":"0001209191-23-021412","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885838/000120919123021412/doc4.xml","form_type":"4"}},{"id":1937036,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":115093,"kind":"person","name":"Feingold Jay","position":1,"cik":"0001885838","reported_name":"Feingold Jay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-03-28T16:45:54.000Z","date":"2023-03-24","kind":"grant","planned":false,"acquired":true,"shares":209803,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest 25% on March 24, 2024, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":730345,"source":{"system":"sec-edgar","filing":"0001209191-23-021412","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885838/000120919123021412/doc4.xml","form_type":"4"}},{"id":1936796,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":16005,"kind":"person","name":"Lewis-Hall Freda C","position":1,"cik":"0001437909","reported_name":"Lewis-Hall Freda C","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-28T16:44:28.000Z","date":"2023-03-24","kind":"grant","planned":false,"acquired":true,"shares":139355,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":206186,"source":{"system":"sec-edgar","filing":"0001209191-23-021409","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1437909/000120919123021409/doc4.xml","form_type":"4"}},{"id":1936524,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":56009,"kind":"person","name":"HUMPHREY RACHEL","position":1,"cik":"0001579781","reported_name":"HUMPHREY RACHEL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-28T16:43:44.000Z","date":"2023-03-24","kind":"grant","planned":false,"acquired":true,"shares":58064,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":58064,"source":{"system":"sec-edgar","filing":"0001209191-23-021408","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1579781/000120919123021408/doc4.xml","form_type":"4"}},{"id":1937096,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":56110,"kind":"person","name":"FLAVIN JOHN L","position":1,"cik":"0001126556","reported_name":"FLAVIN JOHN L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-28T16:43:00.000Z","date":"2023-03-24","kind":"grant","planned":false,"acquired":true,"shares":139355,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":377796,"source":{"system":"sec-edgar","filing":"0001209191-23-021407","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1126556/000120919123021407/doc4.xml","form_type":"4"}},{"id":1936516,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":38545,"kind":"person","name":"Cline Darren S","position":1,"cik":"0001633639","reported_name":"Cline Darren S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-28T16:41:45.000Z","date":"2023-03-24","kind":"grant","planned":false,"acquired":true,"shares":139355,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date."}],"balance_after":216186,"source":{"system":"sec-edgar","filing":"0001209191-23-021405","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1633639/000120919123021405/doc4.xml","form_type":"4"}},{"id":350903,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value per share","published_at":"2023-03-23T20:14:26.000Z","date":"2023-03-17","kind":"purchase","planned":false,"acquired":true,"shares":1811594,"price":2.76,"value":4999999.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The securities were issued under that certain first amendment dated March 16, 2023 to the Amended and Restated License Agreement dated October 14, 2022 between the Reporting Person and the Issuer, pursuant to which the Issuer agreed to issue to the Reporting Person such number of shares of common stock equivalent to $5.0 million at a per share price equal to the closing price of the Issuer's common stock on the business day when the closing price of the Issuer's common stock on the Nasdaq Global Select Market is at or above $2.46 per share on any day between March 16, 2023 and a date that is within 180 days following October 6, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 17, 2023, the closing price of the Issuer's common stock on the Nasdaq Global Select Market was $2.76 per share."}],"balance_after":5952263,"source":{"system":"sec-edgar","filing":"0000078003-23-000052","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000052/primary_doc.xml","form_type":"4/A","original_submission_date":"2023-03-21"}},{"id":350952,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":2863,"kind":"organization","name":"PFIZER INC","symbol":"PFE","position":1,"cik":"0000078003","reported_name":"PFIZER INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15377,"kind":"organization","name":"Pfizer Ventures (US) LLC","position":2,"cik":"0001776087","reported_name":"Pfizer Ventures (US) LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.001 par value per share","published_at":"2023-03-21T22:07:27.000Z","date":"2023-03-17","kind":"purchase","planned":false,"acquired":true,"shares":1811594,"price":2.76,"value":4999999.44,"ownership":{"direct":true},"balance_after":5952263,"source":{"system":"sec-edgar","filing":"0000078003-23-000050","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/78003/000007800323000050/primary_doc.xml","form_type":"4"}}],"next_cursor":"2023-03-21T22:07:27.000000Z,350952"}